Gadolinium

CHMP backs ocrelizumab for relapsing MS in patients aged 10 and older after Phase III showed stronger lesion suppression and comparable relapse control versus fingolimod.

LOI aims to deliver Brazilian rare-earth feedstock to a French separation plant by 2028, supporting magnet-grade Nd/Pr/Dy/Tb supply and industrial Dy/Tb separation by Sep 2026.

Exploration added volume and confidence; reserves ~0.9 Gt. Resources grew mainly at Malmberget; Per Geijer hosts 2.2 Mt REO in situ and phosphorus. EU strategic status granted.

Gadoquatrane, a low-dose MRI contrast agent, shows positive Phase III results. It's under review in the U.S., Japan, and EU for use in adults and children, including neonates.

Gadoquatrane, a low-dose MRI contrast agent, shows positive Phase III results. EU approval could reduce gadolinium exposure by 60% compared to current standards.